Search
Patexia Research
Case number IPR2017-01094

Celltrion Inc. et al. v. Biogen, Inc. > Documents

Date Field Doc. No.PartyDescription
Mar 15, 2017 1031 Reff, et al., Depletion of B Cells in Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20, Blood, 83(2):435-445 (Jan. 15, 1994) Download
Mar 15, 2017 1014 Coiffier, et al., A multicenter, randomized phase II study of rituximab (chimeric anti-CD20 mAb) at two dosages in patients with relapsed or refractor intermediate or high-grade NHL (IHG-NHL) et al., Blood, 90(10):510a (Abstract 2271) (Nov. 15, 1997) Download
Mar 15, 2017 1010 Public Hearing Transcript, Biological Response Modifiers Advisory Committee, Center for Biological Evaluation and Research, Food and Drug Administration, Nineteenth Meeting (July 25, 1997) Download
Mar 15, 2017 1015 Coiffier, et al., Rituximab (Anti-CD20) Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study, Blood, 92(6):1927-1932 (Sept. 15, 1998) Download
Mar 15, 2017 1037 Coiffier, et al., CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, N. Engl. J. Med., 346(4):235-242 (Jan 24, 2002) Download
Mar 15, 2017 1045 Smith, Rituximab (monoclonal anti-CD20 antibody): mechanism of action and resistance, Oncogene, 2(47):7359-7368 (Oct. 20, 2003) Download
Mar 15, 2017 1 Petitioner's Power of Attorney Download
Mar 15, 2017 1029 IDEC Pharmaceuticals Corporation, Form 10-K/A for the Fiscal Year ended December 31, 1997 filed with the U.S. Securities and Exchange Commission Download
Mar 15, 2017 1026 Leget, et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download
Mar 15, 2017 1012 Davis, et al., Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab, J. Clin, Oncol., 17(6):1851-57 (June 1999) Download
Mar 15, 2017 1004 Expert Declaration of Dr. Walter Longo Download
Mar 15, 2017 1049 Eastern Cooperative Oncology Group Protocols Active as of May 19, 1998 Download
Mar 15, 2017 1016 Czuczman, et al., Chemoimmunotherapy of Low-Grade Lymphoma with the Anti-CD20 Anitbody IDEC-C2B8 in Combination with CHOP Chemotherapy, Cancer Invest., 14(Supp. 1):59-61 (Abstract 53) (1996) Download
Mar 15, 2017 1028 Ford, et al., Immunotherapeutic Approaches to Treatment of B-Cell Neoplasms: Focus on Unconjugated Antibodies, Highlights in Oncology Practice, 16(2):40-50 (1998) Download
Mar 15, 2017 1043 Armitage, et al., New Approach to Classifying Non-Hodgkin's Lymphomas: Clinical Features of the Major Histologic Subtypes, J. Clin. Oncol., 16(8):2780-2795 (aUG. 1998) Download
Mar 15, 2017 1021 Anderson, et al., Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation, Blood, 63(6):1524-1433 (June 1984) Download
Mar 15, 2017 1046 Eastern Cooperative Oncology Group E4494 Protocol (1997) Download
Mar 15, 2017 1002 Excerpts from the certified filed history of the '244 patent Download
Mar 15, 2017 1023 Foon, et al., Chapter 111: Lymphomas in Williams Hematology, Fifth Edition, 1076-1096 (Beutler, E. et al. eds., 1995) Download
Mar 15, 2017 1011 Davis, et al., Rituximab: First Report of a Phase II (PII) Trial in NHL Patients (PTS) with Bulky Disease, Blood, 92(10) Suppl. 1):414a (Abstract 1711) (Nov. 15, 1998) Download
Mar 15, 2017 1027 Harris, et al., A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group, Blood, 84(5):1361-1392 (Sept. 1 1994) Download
Mar 15, 2017 1052 DeVita, V.T. et al., Chapter 44: Hodgkin's Disease and the Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice of Oncology, Second Edition (Devita, Jr. et al., eds., 1985) Download
Mar 15, 2017 1007 Eastern Coperative Oncology Group E4494 Patient Consent Form (1997) Download
Mar 15, 2017 1008 Rituxan (Rituximab) Label (Nov. 1997) Download
Mar 15, 2017 1039 FDA FOIA Response Letter (August 26, 2016) Download
Mar 15, 2017 1005 Link, et al., Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate- or High-Grade NHL, Program/Proceedings Am. Soc. Clin. Oncol., 17:3a (Abstract 7), 1998 Download
Mar 15, 2017 1009 Sonneveld, et al., Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advance Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy, J. Clin. Oncol., 13(10):2530-39 (Oct. 1995) Download
Mar 15, 2017 1001 U.S. Patent No. 8,557,244 Download
Mar 15, 2017 1020 Stashenko, et al., Characterization of a Human B Lymphocyte-Specific Anigen, J. Immunol., 125(4):1678-1685 (Oct. 1980) Download
Mar 15, 2017 1003 Expert Declaration of Dr. Izidore Lossos Download
Mar 15, 2017 2 Petitioner's Petition for Inter Partes Review of U.S. Patent No. 8,557,244 Download
Mar 15, 2017 1024 Vose et al., Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients with Previously Untreated, Aggressive Non-Hodgkin's Lymphoma, J. Clin. Oncol., 19(2):389-397 (Jan. 15, 2001) Download
Mar 15, 2017 1025 The Non-Hodgkin's Lumphoma Pathologic Classification Project, National Cancer Institute Sponspored Study of Classifications of Non-Hodgkin's Lymphomas: etc., Cancer, 49(10):2112-2135 (May 15, 1982) Download
Mar 15, 2017 1044 Armitage, Treatment of Non-Hodgkin's Lymphoma, New Engl. J. Med., 328(14):1023-1030 (Apr. 8, 1993) Download
Mar 15, 2017 1051 Eastern Cooperative Oncology GroupE4494 On Study Dates Download
Mar 15, 2017 1019 Fisher, et al., Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma, New. Engl. J. Med., 328(14):1002-1006 (Apr. 8, 1993) Download
Mar 15, 2017 1038 Shipp, et al., Section 3: Non-Hodgkin's Lymphomas, in Cancer: Principles & Practice on Oncology, 5th edition, 2165-2223 (DeVita, V.T. et al., eds. 1997) Download
Mar 15, 2017 1018 Gordon, et al., Comparison fo a Second-Generation Combination Chemotherapeutic Regimen (m-BADOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's Lymphoma, New Engl. J. Med., 327(19):1342-1349 (Nov. 5, 1992) Download
Mar 15, 2017 1006 McNeil, Non-Hodgkin's Lymphoma Trials in Elderly Look Beyond CHOP, J. Nat'l Cancer Inst., 90(4):266-67 (Feb. 18 1998) Download
Mar 15, 2017 1013 Ford, Rituxan (Rituximab), The CAL GAB, Quarterly Newsletter of the Cancer and Leukemia Group B, 7(1):4-5 (Spring 1998) Download
Mar 15, 2017 1034 Anderson, et al., Targeted anti-cancer therapy using rituximab, a chemaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-Cell lymphoma, Biochem. Soc. T., 25(2):705-708 (May 1997) Download
Mar 15, 2017 1004 Expert Declaration of Dr. Walter Longo Download
Mar 15, 2017 1026 Leget, et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download
Mar 15, 2017 1003 Expert Declaration of Dr. Izidore Lossos Download
Mar 17, 2017 1003 Lossos Declaration (Corrected) Download
Mar 17, 2017 1004 Longo Declaration (Corrected) Download
Mar 17, 2017 3 Certificate of Service re Corrected Exhibits Download
Mar 17, 2017 4 Petitioner's Updated Mandatory Notice re Lead Backup Counsel Download
Apr 5, 2017 7 Mandatory Notice Download
Apr 5, 2017 5 Notice of Defective Petition Download
Apr 5, 2017 6 Power of Attorney Download
Apr 7, 2017 1026 (Corrected) Leget, G.A. et al., Use of rituximab, the new FDA-approved antibody, Curr. Opin. Oncol., 10(6):548-551 (Nov. 1998) Download
Apr 7, 2017 8 Notice of Corrected Exhibit Download
May 15, 2017 9 NOTICE OF ACCEPTING CORRECTED PETITION Download
Jul 5, 2017 2002 Ex 2002 Hiddemann 1995 Download
Jul 5, 2017 2003 Ex 2003 Hiddemann 1996 Download
Jul 5, 2017 10 Patent Owner's Preliminary Response Download
Jul 5, 2017 2008 Ex 2008 '172 Patent Download
Jul 5, 2017 2006 Ex 2006 Martelli Download
Jul 5, 2017 2001 Ex 2001 Al Ismail Download
Jul 5, 2017 2009 Ex 2009 Meyer 1997 Download
Jul 5, 2017 2007 Ex 2007 Bio Report Download
Jul 5, 2017 11 Patent Owner's Exhibit List Download
Oct 2, 2017 12 Trial Instituted Document Download
Nov 1, 2017 13 Petitioner's Request for Rehearing Pursuant to 37 C.F.R. Section 42.71(c) and (d) Download
Dec 27, 2017 14 Patent Owner's Updated Mandatory Notice Download
Jan 2, 2018 15 Decision - Denying Petitioner's Request for Rehearing Download
Jan 5, 2018 16 Petitioner's Request for Refund of Post-Institution Fee Download
Jan 12, 2018 17 Notice of Refund Download
Menu